Jalal Rezaei

Jalal Rezaei

Auto-generated profile, based on publicly available information

Jalal Rezaei

Department of Critical Care Nursing, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2024 in Immunopathologia Persa
Verified
Journal Article
Open access
PDF file
SASheida Abbasi
Sheida Abbasi
JRJalal Rezaei
Jalal Rezaei
FBFariba Bazi
Fariba Bazi
MMMoloud Alsadat Mousavi
Moloud Alsadat Mousavi
SRSadaf Rassouli
Sadaf Rassouli
ZMZahra Hamidi Madani
Zahra Hamidi Madani
Introduction: Endometrial cancer is one of the most prevalent female malignancies, with various factors, including metabolic syndrome, contributing to its incidence. Thus, this study aims to evaluate the association between metabolic syndrome and the risk of endometrial carcinoma. Materials and Methods: In this systematic review and meta-analysis, two independent authors searched electronic databases, including Cochrane, PubMed, ProQuest, Web of Science, and the Google Scholar search engine up to May 16, 2024. Data analysis was conducted using STATA 14 software with a significance level of P < 0.05 for all tests. Results: A pooled analysis of 12 observational studies found that metabolic syndrome elevated the risk of endometrial carcinoma by 37% overall (OR: 1.37, 95% CI: 1.33, 1.42), 35% in cohort studies (OR: 1.35, 95% CI: 1.29, 1.42), and 40% in case-control studies (OR: 1.40, 95% CI: 1.33, 1.48). However, hypertension increased the risk of endometrial carcinoma by 25% (OR: 1.25, 95% CI: 1.18, 1.33), fasting hyperglycemia by 25% (OR: 1.25, 95% CI: 1.15, 1.37), hypertriglyceridemia by 17% (OR: 1.17, 95% CI: 1.13, 1.21), low high density lipoprotein (HDL) by 20% (OR:1.20, 95% CI: 1.12, 1.28), increased waist circumference by 59% (OR:1.59, 95% CI: 1.43, 1.77), pre-menopausal period by 67% (OR:1.67, 95% CI: 1.38, 2.02), and post-menopausal period by 61% (OR: 1.61, 95% CI: 1.17, 2.21). Likewise, obesity almost doubled the risk of endometrial carcinoma (OR: 2.13, 95% CI: 1.65, 2.75). Conclusion: Metabolic syndrome increases the risk of endometrial carcinoma, with obesity being the most dangerous risk factor for endometrial cancer. Thus, managing metabolic disorders in women can be an important step toward reducing the incidence of endometrial cancer. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024551509) and Research Registry (UIN: reviewregistry1838).

25 May 2024 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
RGReza Ghaderi
Reza Ghaderi
ZAZahra Abdollahi
Zahra Abdollahi
MMMohammad Hamidi Madani
Mohammad Hamidi Madani
ADAnna Ghorbani Doshantapeh
Anna Ghorbani Doshantapeh
BMBoshra Moghimi
Boshra Moghimi
RARasoul Jafari Arismani
Rasoul Jafari Arismani
Introduction: Prostate cancer is among the most frequent neoplasms of the male reproductive system, and its relationship with serum vitamin D level is a controversial subject. The present study intended to investigate the relationship between serum vitamin D levels and the risk of prostate carcinoma. Materials and Methods: This study is a systematic review and meta-analysis based on the PRISMA tool. The search was conducted in databases Web of Science, Cochrane, ProQuest, PubMed, and Google Scholar Search Engine until December 1, 2023. Data was analyzed using STATA 14 software. Results: There was no significant relationship between serum vitamin D levels lower than 50 nmol/L (vitamin D level <50 nmol/L) and prostate cancer. In Finland, the risk of prostate carcinoma in male individuals with serum vitamin D levels lower than 50 nmol/L was 34% higher (OR: 1.34, 95% CI: 1.14, 1.54). In South Korea, on the other hand, serum vitamin D levels lower than 50 nmol/L prevented prostate cancer (OR: 0.94, 95% CI: 0.90, 0.99). There was no significant relationship between the serum vitamin D levels lower than 50 nmol/L and prostate neoplasm in men aged 60 to 69 years old (OR: 0.95, 95% CI: 0.83, 1.07), in men 50 to 59 years old. On the other hand, serum vitamin D levels lower than 50 nmol/L increased the risk of prostate tumor by 32% (OR: 1.32, 95% CI: 1.13, 1.55). Furthermore, no significant relationship was observed between serum vitamin D levels higher than 50 nmol/L (vitamin D level ≥ 50 nmol/L) and the risk of prostate cancer (OR: 1.06, 95% CI: 0.99, 1.14). Conclusion: Generally, there was no significant relationship between serum vitamin D levels and the risk of prostate carcinoma; however, the relationship in some subgroups was statistically significant. We therefore recommend conducting additional studies on this subject. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42023491012) and Research Registry (UIN: reviewregistry1773) website.

6 February 2025 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
RHRanin Haghighi
Ranin Haghighi
JRJalal Rezaei
Jalal Rezaei
FKFatemeh Khaleghi
Fatemeh Khaleghi
MMMohammad Hamidi Madani
Mohammad Hamidi Madani
HSHussein Soleimantabar
Hussein Soleimantabar
RARasoul Jafari Arismani
Rasoul Jafari Arismani
Introduction: Kidney and urinary tract stones are a common health concern, with a rising global incidence and significant impact on patient quality of life. Accurate diagnosis and effective management of these stones rely heavily on radiological imaging modalities. This systematic review aimed to synthesize the existing literature on preferred radiological modalities for diagnosing and managing kidney and urinary tract stones, focusing on their diagnostic accuracy, clinical efficacy, and impact on treatment outcomes. Methods: This systematic review was conducted based on PRISMA guidelines to evaluate preferred radiological modalities for diagnosing and managing kidney and urinary tract stones. A comprehensive literature search across multiple databases, including PubMed, Embase, Cochrane Library, Scopus, and Google Scholar, was conducted up to July 2024, using a comprehensive set of MeSH keywords. Quality assessment was performed using the STROBE checklist, with medium and high-quality studies considered acceptable. Data extraction by two independent reviewers captured essential information, with discrepancies resolved through discussion or consultation with a third reviewer. Results: The results of 12 included studies in this review indicated that, while CT scans are the most accurate imaging modality for diagnosing kidney and urinary tract stones, ultrasound presents a viable alternative due to its lower radiation exposure. Most studies reported ultrasound sensitivities above 55% and specificities over 95% compared to CT, although some studies noted significantly lower sensitivities. Additionally, X-ray imaging showed limitations, with sensitivities of only 46% to 57%, particularly for smaller stones. Conclusion: This study highlights that while CT scans are the gold standard for diagnosing kidney and urinary tract stones due to their accuracy, ultrasound presents a valuable alternative as an initial diagnostic tool, primarily because of its lower radiation exposure, which enhances patient safety, especially for those needing repeated imaging. Furthermore, the limitations of X-ray imaging in detecting smaller stones caution against its exclusive use. The review also emphasizes the importance of balancing diagnostic accuracy with safety when considering high-dose versus low-dose CT scans. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024579547) and Research Registry (UIN: reviewregistry1873) websites.

2 October 2024 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
PDF file
SBShahriar Barkhordari
Shahriar Barkhordari
RARoya Azouji
Roya Azouji
FYFarangis Yazdanjou
Farangis Yazdanjou
ANArash Neshati
Arash Neshati
AAAmirhosein Abareghi
Amirhosein Abareghi
JRJalal Rezaei
Jalal Rezaei
Introduction: Sjogren’s syndrome is an autoimmune disorder with variable prevalence in different parts of the world. This study aims to estimate the prevalence of Sjogren’s syndrome worldwide using a systematic review and meta-analysis. Materials and Methods: For this study, we searched the databases of PubMed, ProQuest, Cochrane, Web of Science, and the Google Scholar search engine without any time limit until February 17, 2024. We used STATA 14 software for data analysis, and the significance level was set at P<0.05. Results: Combining the findings of 24 observational studies with a total of 211349 participants, we concluded that the overall prevalence of Sjogren’s syndrome in the world and the female population was (13%; [95% CI: 10%, 16%]) and (15% [95% CI: 4%, 26%]), respectively. The worldwide prevalence of Sjogren’s syndrome in cohort studies and cross-sectional studies was (14% [95% CI: 10%, 19%]) and (10% [95% CI: 7%, 14%]), respectively. However, the prevalence of primary Sjogren’s syndrome was (7% [95% CI: 5%, 9%]) and the prevalence of secondary Sjogren syndrome was (9% [95% CI: 6%, 13%]). Additionally, the prevalence of Sjogren’s syndrome among the age groups of 20-29, 30-39, 40-49, 50-59, 60-69, and 70-79 years was (31% [95% CI: 30%, 42%]), (4% [95% CI: 1%, 6%]), (7% [95% CI: 5%, 10%]), (24% [95% CI: 15%, 33%]), (22% [95% CI: 2%, 42%]), and (5% [95% CI: 1%, 9%]), respectively. Conclusion: Sjogren’s syndrome has a high overall prevalence in the world, and considering the adverse outcomes of this disease, there should be measures taken to control and screen the prevalence of Sjogren’s disease. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024513783) and Research Registry (UIN: reviewregistry1793) website.

16 November 2024 in Journal of Preventive Epidemiology
Verified
Journal Article
Open access
PDF file
MAMeysam Alipour
Meysam Alipour
JRJalal Rezaei
Jalal Rezaei
VRVenus Shahabi Rabori
Venus Shahabi Rabori
MAMeysam Arbuzia
Meysam Arbuzia
ANAmin Norouzbeygi
Amin Norouzbeygi
MFMobin Forghan
Mobin Forghan
This review article examines the association between sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and the risk of limb amputation, particularly in patients with type 2 diabetes mellitus. This review aims to provide a comprehensive understanding of the risks associated with SGLT2i therapy and to inform future research directions in this area. While SGLT2i medications, such as canagliflozin, are recognized for their cardiovascular and renal benefits, emerging evidence suggests a potential increase in the risk of lower limb amputations (LLAs) among users compared to non-users of SGLT2i. This review synthesizes findings from various studies that report a slightly elevated risk of amputation linked to SGLT2i therapy, with mechanisms proposed including diuretic-induced hypovolemia and the partial inhibition of sodium-glucose cotransporter 1. Factors such as pre-existing peripheral artery disease (PAD), sensory neuropathy, and poor foot health are identified as significant risk enhancers for lower limb amputations in this patient population. In conclusion, patients with these conditions are at increased risk of limb ischemia and subsequent amputation, and the administration of SGLT2 inhibitors may potentially further increase this risk.

17 April 2024 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
RJRezaei Jalal
Rezaei Jalal
SGShahrzad Ghiyasvandian
Shahrzad Ghiyasvandian
ARAzouji Roya
Azouji Roya
ZMZakerimoghadam Masoumeh
Zakerimoghadam Masoumeh
Common side effects after stem cell transplantation (SCT), such as anorexia, nausea, and vomiting, can disrupt the quality of life of patients. Therefore, this study aimed to determine the effect of self-care education with smart phone applications on the severity of nausea and vomiting after SCT in leukemia patients. In this clinical trial study, using the blocked randomization method 104 leukemia patients undergoing SCT were assigned to two groups, intervention and control. The patients of the Control Group received routine care, and the Intervention Group received self-care education with a smart mobile phone application, in addition to routine care. Two weeks, one month, and three months after the start of the intervention, the severity of nausea and vomiting was evaluated using the visual analog scale (VAS) and the Khavar Oncology scale, both of which were completed by both Control and Intervention Groups. Data were analyzed using chi-square, Fisher's exact, Mann-Whitney, and Friedman tests using the Statistical Package for Social Sciences version 25 software. The severity of nausea and vomiting in leukemia patients undergoing SCT was significantly different in the two groups at all three timepoints (two weeks, one month, and three months) after transplantation (p-value = 0.000). The severity of nausea and vomiting after SCT in leukemia patients was improved by self-care education with a smart phone application. Therefore, this method is recommended to reduce the severity of nausea and vomiting in leukemia patients who undergo transplantation.